Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Other Events

ME Staff 8-k
-
0
Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Other Events

Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Other Events
Item 8.01 Other Events.

On November27, 2018, Eagle Pharmaceuticals,Inc. issued a press release announcing positive results of a pre-clinical study conducted to evaluate the effects of RYANODEX®(dantrolene sodium) in Acute Radiation Syndrome.

A copy of the full text of the press release referenced above is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

99.1

Press Release dated November27, 2018


EAGLE PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a18-40649_1ex99d1.htm EX-99.1 Exhibit 99.1     For Immediate Release   Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)   —Eagle to explore ARS indication to treat individuals exposed to high doses of radiation such as nuclear power plant leakage or nuclear weapons; additional research ongoing to evaluate hematopoietic syndrome in certain cancer patients undergoing radiation therapy—   WOODCLIFF LAKE,…
To view the full exhibit click here

About Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.